The experience of neuroprotective therapy of primary open -angle glaucoma based on the use of various forms of Mexidol

Authors:
E.S. LEONOVA^1,2, S.V. POLYAKOV^1,2, M.A. POZDNYAKOVA², E.P. YARYGINA³, S.O. SEMISYNOV²

^1.NGO "Road Clinical Hospital at Gorky Station of JSC "Russian Railways", Inter-Road Ophthalmology Center
^2.State Budgetary Educational Institution of Higher Professional Education "Nizhny Novgorod State Medical Academy"
^3.State Budgetary Healthcare Institution of the Nizhny Novgorod Region "City Hospital No. 35", City Glaucoma Center

Place of publication:
VESTNIK OPHTHALMOLOGII, 6, 2015

Abstract:
The aim was to develop a neuroprotective treatment algorithm for the follow-up of railway workers with primary open-angle glaucoma (POAG) based on the efficacy of the step-by-step administration of intravenous and tablet forms of Mexidol. Material and methods. The study included patients — workers of various professions at Russian Railways with stage I-III POAG and compensated intraocular pressure (IOP). Mexidol was prescribed at a dose of 250 mg intravenously by drip for 5 days in a day hospital setting, then at an outpatient dose of 125 mg orally 3 times a day for 3 months. During the first, second, and third visits, patients underwent a comprehensive ophthalmological examination using high-tech monitoring techniques. Results. Data from 58 patients (96 eyes) were analyzed. A significant improvement in perimetry and optical coherence tomography parameters was only achieved at the third visit, after completion of treatment with Mexidol tablets. Patients with stages I-II of the disease showed the greatest effect from neuroprotective therapy. Conclusion. The results obtained during the study allow us to recommend both combination therapy with Mexidol (injectable and tablet forms) and long-term (3 months) isolated use of the tablet form for patients with primary open-angle glaucoma. Neuroprotective therapy with Mexidol is most effective in the early stages of the disease.